Business
AstraZeneca antibody cocktail succeeds in late-stage study to treat COVID-19, company says – Sydney Morning Herald
The findings are a boost to the British drug maker’s efforts to develop coronavirus medicines beyond vaccines.
Well be continuing discussions with regulators around this new data, she said of the trial results.
The trial took place across 13 countries and involved more than 900 adult participants, with one half receiving AZD7442 and the rest a placebo. Full trial…
Continue Reading
